Antipyrine

Mechanism-of-action class: Unknown Cellular or Molecular Interaction.

• Toothaches, swollen gums, jaw pain.

SUGGESTED DOSAGE One dropper under tongue two times daily. Acute symptoms ½ dropper under tongue every 30 minutes for two hours.

Use only if cap seal is unbroken. If pregnant or breastfeeding, ask a healthcare professional before use. Keep this and all medication out of the reach of children.

1. 1Diarrhoea336.8%
2. 2Pain336.8%
3. 3Headache306.2%
4. 4Fatigue296.0%
5. 5Nausea275.6%
6. 6Arthralgia265.3%
7. 7Dizziness255.1%
8. 8Pain In Extremity214.3%
9. 9Asthenia183.7%
10. 10Abdominal Pain Upper173.5%
11. 11Eye Pain173.5%
12. 12Fall173.5%
13. 13Gait Disturbance173.5%
14. 14Muscle Spasms173.5%
15. 15Dyspnoea163.3%

Recent PubMed references pinned to Antipyrine as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• Protective Effect of Edaravone on Doxorubicin-Induced Thyroid Dysfunction in Rats Revealed by (99m)Tc Pertechnetate Thyroid Gland Scintigraphy and Biochemical Methods.
  Medicina (Kaunas, Lithuania) · 2026 · Kalın M, Aygun H, Karakullukcu HK, et al.
  PMID 42195147DOI 10.3390/medicina62050894
• Promising Synthetic Antioxidants of Dimethyltin(IV) Formulations Derived From 4-Acylated Edaravone: Design, DFT Assisted Optimized Molecular Structure and Mechanistic Insights into SET Versus HAT Pathways for Antioxidant Activity.
  Journal of biochemical and molecular toxicology · 2026 · Kumawat A, Soni K, Saxena S, et al.
  PMID 42101074DOI 10.1002/jbt.70832
• Adverse events in different administration routes of Edaravone: A pharmacovigilance study based on the FDA adverse event reporting system.
  PloS one · 2026 · Ge D, Wu L, Yang J, et al.
  PMID 41973722DOI 10.1371/journal.pone.0346797
• Effect of edaravone on synaptic damage in Alzheimer's disease via Rho/ROCK signaling.
  Pakistan journal of pharmaceutical sciences · 2026 · Li Y, Lai Q, Li Q, et al.
  PMID 41934300DOI 10.36721/PJPS.2026.39.6.154.1
• Trial of Edaravone for severe hypoxic ischemic encephalopathy in adults: a double-blind placebo-controlled study.
  Journal of neurology · 2026 · Razmeh S, Karimi AA, Dashti AM, et al.
  PMID 41832246DOI 10.1007/s00415-026-13723-2
• Prospective Open-Label Safety Study of Edaravone Dexborneol in Filipino Patients With Acute Ischemic Stroke.
  Brain and behavior · 2026 · Sabellano ZF, Pedregosa B 2nd, Batino LK, et al.
  PMID 41804749DOI 10.1002/brb3.71272
• Borneol-Edaravone mitigates ischemic brain injury in MCAO rats.
  Journal of neuroimmunology · 2026 · Zhuang XF, Zhang T, Zeng YQ, et al.
  PMID 41793953DOI 10.1016/j.jneuroim.2026.578901
• Edaravone dexborneol promotes oligodendrocyte precursor cell proliferation and differentiation to repair white matter and improve long-term outcomes after ischemic stroke.
  Brain research bulletin · 2026 · Han W, Duan T, Xu J, et al.
  PMID 41763584DOI 10.1016/j.brainresbull.2026.111797

The 10 most recently updated of 47 ClinicalTrials.gov registrations naming Antipyrine as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke
  Completed · Phase 2 · Interventional · 36 enrolled · Tanabe Pharma Corporation
  NCT00821821updated 2026-06-04
• Safety Study of Oral Edaravone Administered in Subjects With ALS
  Completed · Phase 3 · Interventional · 185 enrolled · Tanabe Pharma America, Inc.
  NCT04165824updated 2026-05-22
• Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)
  Completed · Phase 3 · Interventional · 124 enrolled · Tanabe Pharma America, Inc.
  NCT04577404updated 2026-05-22
• Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS
  Terminated · Phase 3 · Interventional · 384 enrolled · Tanabe Pharma America, Inc.
  NCT04569084updated 2026-05-22
• Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis
  Completed · Phase 1 · Interventional · 9 enrolled · Tanabe Pharma Corporation
  NCT04176224updated 2026-05-22
• Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS
  Completed · Phase 3 · Interventional · 15 enrolled · Tanabe Pharma Corporation
  NCT05568615updated 2026-05-22
• Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy
  Completed · Phase 1 · Interventional · 6 enrolled · Tanabe Pharma Corporation
  NCT04254913updated 2026-05-22
• Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Subjects (Food Effect Study)
  Completed · Phase 1 · Interventional · 16 enrolled · Tanabe Pharma Corporation
  NCT05342597updated 2026-05-22
• Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study)
  Completed · Phase 1 · Interventional · 84 enrolled · Tanabe Pharma Corporation
  NCT04481789updated 2026-05-22
• Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS
  Terminated · Phase 3 · Interventional · 202 enrolled · Tanabe Pharma America, Inc.
  NCT05151471updated 2026-05-22

Frequently asked questions

How does Antipyrine work?

Mechanism-of-action class: Unknown Cellular or Molecular Interaction.

What is Antipyrine used for?

According to FDA labeling, Antipyrine carries indications including: Toothaches, swollen gums, jaw pain.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.

What class of drug is Antipyrine?

Antipyrine is classified as Analgesics and anesthetics, Pyrazolones, Unknown Cellular or Molecular Interaction, Unknown Physiological Effect.